Sanofi India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 47.1%)
- ✓Efficient capital deployment (ROCE 49.2%)
- ✓Attractively valued vs sector (P/E 16.5x vs industry 48.9x)
- ✓Virtually debt-free
- ✓Regular dividends — yield 2.4%
- ✓Near 52-week low — potential value zone (₹3,054)
Concerns
- ✗High premium to book value (P/B 9.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SANOFI · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| FII | 6.31% | 6.11% | 5.81% | 5.78% | 5.64% | 5.58% |
| DII | 22.51% | 22.88% | 22.60% | 22.62% | 22.94% | 23.02% |
| Public | 10.78% | 10.61% | 11.21% | 11.20% | 11.04% | 11.01% |
Corporate Events
Dividend - Rs 48 Per Share
Interim Dividend - Rs 75 Per Share
Dividend - Rs 117 Per Share
Demerger
Annual General Meeting
Dividend - Rs 117 Per Share
Interim Dividend - Rs 50 Per Share
Latest News
All news →Sanofi India partners MP Health Mission for rare disease care
*Sanofi India partners MP Health Mission for rare disease care.* The collaboration with NHM Madhya Pradesh aims to expand access to treatment for non-communicable and rare diseases. Focus will be on improving diagnosis and patient support systems. **No financial details** of the partnership were disclosed. 📊 *STOCKS:* SANOFI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #pharma
12 stocks set ex-dates for dividends, splits, bonuses next week
*12 stocks including Sanofi India, Schaeffler, and CRISIL announce ex-dates next week for dividend payouts up to **₹101**, bonus issues, and stock splits.* Corporate actions include distributions and capital restructuring. Traders should note ex-date implications for positions and settlement. Portfolio adjustments advised for affected holdings. 📊 *STOCKS:* SANOFI | SCHAEFFLER | CRISIL | 🏢 *SECTOR:* Multi-sector | #MEDIUMIMPACT #dividend
Sanofi India posts strong earnings with positive momentum ahead
*Sanofi India demonstrates strong earnings performance with positive catalysts beyond current results.* The pharmaceutical company is showing **promising earnings** trajectory with **additional growth drivers** on the horizon. Analysts indicate further upside potential beyond reported numbers, suggesting momentum continuation. This positions the stock favorably for medium-term investors tracking pharma sector strength. 📊 *STOCKS:* $SANOFI | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #EarningsBeat